Current options for the treatment of locally advanced and metastatic renal cell carcinoma : focus on sunitinibRAVAUD, Alain.European journal of cancer. Supplement (1990). 2007, Vol 5, Num 7, pp 4-11, issn 1359-6349, 8 p.Article

Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinomaRAVAUD, Alain.European journal of cancer. Supplement (1990). 2007, Vol 5, Num 7, pp 20-27, issn 1359-6349, 8 p.Article

Le mécanisme de l'angiogénèse tumoraleRAVAUD, Alain.Progrès en urologie (Paris). 2007, Vol 17, Num 1, pp 144-147, issn 1166-7087, 4 p., SUP1Article

Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerationsRAVAUD, Alain.European journal of cancer. Supplement (1990). 2007, Vol 5, Num 7, issn 1359-6349, 36 p.Serial Issue

Parcours de soins en cancérologie et financement = Cancer treatment process and fundingRAVAUD, Alain.Journal de gestion et d'économie médicales. 2014, Vol 32, Num 2, pp 105-112, issn 2262-5305, 8 p.Conference Paper

Optimisation of sunitinib therapy in metastatic renal cell carcinoma : adverse-event managementNEGRIER, Syluie; RAVAUD, Alain.European journal of cancer. Supplement (1990). 2007, Vol 5, Num 7, pp 12-19, issn 1359-6349, 8 p.Article

Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin InhibitorsRAVAUD, Alain; WALLERAND, Hervé.European urology. Supplement. 2009, Vol 8, Num 10, pp 793-798, issn 1569-9056, 6 p.Article

Caractérisation de composants optiques par des techniques d'intelligence artificielle = Characterization of optical components using artificial intelligence techniquesROBERT, Stéphane; MURE-RAVAUD, Alain.Photoniques (Orsay). 2002, Num 6, pp 36-40, issn 1629-4475, 5 p.Article

Case Report 1. Sunitinib malate in patients with pre-existing haematological abnormalitiesBAMIAS, Aristotle.European journal of cancer. Supplement (1990). 2007, Vol 5, Num 7, pp 28-29, issn 1359-6349, 2 p.Article

Thérapie cellulaire dans les tumeurs solides = Cell therapy in solid tumorsRAVAUD, Alain.Bulletin du cancer. 2001, Vol 88, Num 1, pp 91-100, issn 0007-4551Article

Current and Future Treatment Options for Metastatic Renal Cell CarcinomaBRACARDA, Sergio; RAVAUD, Alain.European urology. Supplement. 2009, Vol 8, Num 10, pp 799-808, issn 1569-9056, 10 p.Article

Case Report 3. Sunitinib malate in patients with cerebellar metastasesNEGRIER, Syluie.European journal of cancer. Supplement (1990). 2007, Vol 5, Num 7, pp 32-34, issn 1359-6349, 3 p.Article

Cancer de la vessieMASSARD, Christophe; RAVAUD, Alain.Bulletin du cancer. 2010, Vol 97, Num JUN, issn 0007-4551, 57 p., NSSerial Issue

Actualités sur le cancer du rein = What is new in renal cell carcinomaRAVAUD, Alain; BAY, Jacques-Olivier.Bulletin du cancer. 2002, Vol 89, Num 1, pp 31-36, issn 0007-4551Article

What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?CALVO, Emiliano; RAVAUD, Alain; BELLMUNT, Joaquim et al.Cancer treatment reviews. 2013, Vol 39, Num 4, pp 366-374, issn 0305-7372, 9 p.Article

Prise en charge du patient métastatique dans le cancer de la vessie = Treatment strategies for metastatic patients in bladder cancerTHEODORE, Christine.Bulletin du cancer. 2010, Vol 97, Num JUN, issn 0007-4551, S27-S33, NSArticle

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell CarcinomaBRACARDA, Sergio; RAVAUD, Alain; CHIODI, Marino et al.European urology. Supplement. 2009, Vol 8, Num 10, pp 815-819, issn 1569-9056, 5 p.Article

DISPOSITIFS MICRO-OPTIQUES ENFOUIS PAR ADHERENCE MOLECULAIRE = Microoptics devices buried by Wafer Direct BondingPandraud, Gregory; Mure Ravaud, Alain.1998, 148 p.Thesis

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implicationsDANESI, Romano; BONI, Joseph P; RAVAUD, Alain et al.Cancer treatment reviews. 2013, Vol 39, Num 7, pp 784-792, issn 0305-7372, 9 p.Article

Prise en charge thérapeutique des tumeurs de vessie n'envahissant pas le muscle vésical (TVNIM) = Management of non invasive bladder tumours (NMIBC)WALLERAND, H.Bulletin du cancer. 2010, Vol 97, Num JUN, issn 0007-4551, S11-S17, NSArticle

Case Report 2. Severe erythema multiforme induced by two consecutive anti-angiogenic drugsDILHUYDY, Marie-Sarah; JOUARY, Thomas; GOMEZ, Aurélie et al.European journal of cancer. Supplement (1990). 2007, Vol 5, Num 7, pp 30-31, issn 1359-6349, 2 p.Article

Chimiothérapie des patients atteints de cancer de vessie et unfit = Chemotherapy in unfit bladder cancer patientsGOLDWASSER, F; MIR, O; ROPERT, S et al.Bulletin du cancer. 2010, Vol 97, Num JUN, issn 0007-4551, S35-S41, NSArticle

Séminaire de l'étude nationale des coûts à méthodologie commune, Bordeaux, 7 et 8 novembre 2013. Restitution des CommunicationsRAVAUD, Alain; CHAUCHAT, Aymeric; HOLLA, Housseyni et al.Journal de gestion et d'économie médicales. 2014, Vol 32, Num 2, pp 105-162, issn 2262-5305, 58 p.Conference Paper

Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemiaDILHUYDY, Marie-Sarah; JOUARY, Thomas; DEMEAUX, Hélène et al.British journal of haematology. 2007, Vol 137, Num 6, issn 0007-1048, 490Article

Protein kinase inhibitors in renal cell carcinomaDASTE, Amaury; GRELLETY, Thomas; GROSS-GOUPIL, Marine et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 3, pp 337-351, issn 1465-6566, 15 p.Article